Indocyanine Green Imaging for Rotator Cuff Surgery
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to improve outcomes for individuals undergoing rotator cuff surgery, a common procedure for shoulder injuries. Researchers are testing a dye called Indocyanine Green (ICG) to enhance visibility of blood flow during surgery, which might help predict and prevent future tears. Participants will receive one of three different doses of ICG during their surgery to determine the optimal amount. Ideal candidates for this trial have a rotator cuff tear and plan to have it repaired through arthroscopic surgery. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to experience this innovative approach.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Indocyanine Green (ICG) has been safely used in medical tests for over 30 years, aiding doctors in visualizing blood vessels more clearly during surgery. Some studies have applied ICG in procedures like rotator cuff repair to assess blood flow, with patients generally tolerating it well. However, reports have noted some mild side effects, such as itching or rash. As this trial is in its early phase, it aims to determine a safe dose of ICG for this specific use. The different doses being tested (7.5 mg, 12.5 mg, and 25 mg) are designed to provide clear imaging while minimizing side effects.12345
Why are researchers excited about this trial?
Researchers are excited about using Indocyanine Green (ICG) in rotator cuff surgery because it enhances surgical precision. Unlike traditional imaging methods, ICG binds to proteins in the blood, allowing surgeons to visualize blood vessels more clearly during the procedure. This improved visualization can potentially lead to better surgical outcomes and faster recovery for patients. By offering doses of 7.5 mg, 12.5 mg, and 25 mg, the trial aims to determine the optimal amount for the best surgical clarity, making it a promising advancement in surgical techniques.
What evidence suggests that Indocyanine Green is effective for visualizing rotator cuff vascularity?
Research shows that using Indocyanine Green (ICG) can improve outcomes in rotator cuff surgery. In this trial, participants will receive different doses of ICG (7.5 mg, 12.5 mg, or 25 mg) during surgery. Studies have found that patients who underwent surgery with ICG guidance experienced less pain six months later compared to those without ICG. ICG enhances the surgeon's ability to see blood vessels during the procedure, potentially improving rotator cuff repair. This visibility allows the surgeon to identify areas with good blood flow, crucial for healing. ICG has been safely used in other surgeries to enhance blood vessel visibility, suggesting its potential benefits in rotator cuff surgeries as well.12367
Who Is on the Research Team?
Kirk Campbell, MD
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for adults between 18 and 79 years old who are scheduled for arthroscopic repair of full or partial thickness rotator cuff tears. It's not suitable for pregnant individuals, those with recent iodide-based radiology studies, or anyone allergic to iodides.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of three doses of Indocyanine Green (ICG) intravenously during arthroscopic surgery to evaluate rotator cuff vascularity
Follow-up
Participants are monitored for safety and effectiveness after surgery, with assessments of rotator cuff vascularity using AIM arthroscopy videos
What Are the Treatments Tested in This Trial?
Interventions
- Indocyanine Green
Indocyanine Green is already approved in United States, European Union, China, Japan for the following indications:
- Diagnostic imaging agent for various medical procedures including sentinel lymph node mapping
- Diagnostic imaging agent for various medical procedures including sentinel lymph node mapping
- Diagnostic imaging agent for various medical procedures including sentinel lymph node mapping, liver function testing
- Diagnostic imaging agent for various medical procedures including sentinel lymph node mapping, liver function testing
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor